Phylloceuticals2
Phylloceuticals2
  • Home
  • Our Team
    • OUR TEAM
    • Bill Brydges, M.S.
    • Dan Hanson, M.S.
    • R. Barry Holtz, Ph.D.
    • Susan Stipa
    • Mark Brown, Ph.D.
    • Lynn Dickey, Ph.D.
    • Curt Cornwell
    • Kathleen Brunner
  • Technology
  • Markets
  • News
    • News
    • Phylloside Chats
    • Press Release
  • Contact Us
  • More
    • Home
    • Our Team
      • OUR TEAM
      • Bill Brydges, M.S.
      • Dan Hanson, M.S.
      • R. Barry Holtz, Ph.D.
      • Susan Stipa
      • Mark Brown, Ph.D.
      • Lynn Dickey, Ph.D.
      • Curt Cornwell
      • Kathleen Brunner
    • Technology
    • Markets
    • News
      • News
      • Phylloside Chats
      • Press Release
    • Contact Us
  • Home
  • Our Team
    • OUR TEAM
    • Bill Brydges, M.S.
    • Dan Hanson, M.S.
    • R. Barry Holtz, Ph.D.
    • Susan Stipa
    • Mark Brown, Ph.D.
    • Lynn Dickey, Ph.D.
    • Curt Cornwell
    • Kathleen Brunner
  • Technology
  • Markets
  • News
    • News
    • Phylloside Chats
    • Press Release
  • Contact Us

Lynn Dickey, Ph.D.

Lynn Dickey, Ph.D., has an extensive background leading and managing Research and Development activities of cross-functional groups in product and technology development with a focus on plant-made pharmaceuticals. Dr. Dickey was previously the VP of Research and Technology at Biolex Therapeutics where she oversaw the development of the Lemna plant-based core technology including genetic engineering, bioanalytics, product development and design of the aseptic biomanufacturing format. She continued her work with this technology at Synthon Pharmaceuticals, as the VP of R & D and General Manager of the US bioproduction site. Prior to Biolex, Dr. Dickey was a Research Assistant Professor in the Department of Botany at North Carolina State University where she led research programs focused the molecular biology of gene expression in transgenic plants. 

  • Home
  • Terms and Conditions